Last reviewed · How we verify
Tenofovir, Emtricitabine, Raltegravir
This combination of three antiretroviral drugs inhibits HIV replication by blocking reverse transcriptase and integrase enzymes, preventing viral DNA synthesis and integration into the host genome.
This combination of three antiretroviral drugs inhibits HIV replication by blocking reverse transcriptase and integrase enzymes, preventing viral DNA synthesis and integration into the host genome. Used for HIV-1 infection in treatment-naïve and treatment-experienced patients, HIV-1 infection as part of combination antiretroviral therapy.
At a glance
| Generic name | Tenofovir, Emtricitabine, Raltegravir |
|---|---|
| Sponsor | Hospital Clinic of Barcelona |
| Drug class | Antiretroviral combination therapy (NRTI/NtRTI + INSTI) |
| Target | HIV reverse transcriptase and HIV integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Tenofovir and emtricitabine are nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs/NtRTIs) that block the reverse transcriptase enzyme, preventing conversion of viral RNA to DNA. Raltegravir is an integrase strand transfer inhibitor (INSTI) that prevents integration of viral DNA into the host chromosome. Together, they provide complementary mechanisms to suppress HIV replication.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced patients
- HIV-1 infection as part of combination antiretroviral therapy
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
- Renal impairment (tenofovir-related)
- Bone density loss
- Lactic acidosis (rare)
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
- Post-Exposure Prophylaxis in Health Care Workers (PHASE4)
- Research on the Psychological Status of Patients With HIV-1 Infection
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: